Robocap Asset Management Ltd Has $6.47 Million Stock Holdings in PROCEPT BioRobotics Corporation (NASDAQ:PRCT)

Robocap Asset Management Ltd raised its stake in PROCEPT BioRobotics Corporation (NASDAQ:PRCT - Free Report) by 21.9% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 111,004 shares of the company's stock after buying an additional 19,933 shares during the period. PROCEPT BioRobotics comprises about 4.8% of Robocap Asset Management Ltd's portfolio, making the stock its 8th biggest position. Robocap Asset Management Ltd owned 0.20% of PROCEPT BioRobotics worth $6,467,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently made changes to their positions in the stock. Teacher Retirement System of Texas grew its position in shares of PROCEPT BioRobotics by 16.1% in the 1st quarter. Teacher Retirement System of Texas now owns 11,080 shares of the company's stock valued at $646,000 after buying an additional 1,537 shares during the last quarter. FSM Wealth Advisors LLC acquired a new position in shares of PROCEPT BioRobotics in the 1st quarter valued at about $251,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of PROCEPT BioRobotics by 9.0% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,779 shares of the company's stock valued at $527,000 after purchasing an additional 723 shares during the period. Diversified Trust Co lifted its stake in shares of PROCEPT BioRobotics by 54.6% in the 1st quarter. Diversified Trust Co now owns 7,187 shares of the company's stock valued at $419,000 after purchasing an additional 2,538 shares during the period. Finally, Bessemer Group Inc. lifted its stake in shares of PROCEPT BioRobotics by 50.7% in the 1st quarter. Bessemer Group Inc. now owns 10,900 shares of the company's stock valued at $635,000 after purchasing an additional 3,665 shares during the period. Institutional investors own 89.46% of the company's stock.

PROCEPT BioRobotics Stock Down 4.3%

PROCEPT BioRobotics stock traded down $2.56 during midday trading on Friday, reaching $56.65. The stock had a trading volume of 548,062 shares, compared to its average volume of 846,442. PROCEPT BioRobotics Corporation has a 12 month low of $47.04 and a 12 month high of $103.81. The company has a market capitalization of $3.13 billion, a P/E ratio of -33.32 and a beta of 1.07. The company has a fifty day moving average price of $58.29 and a two-hundred day moving average price of $62.89. The company has a current ratio of 8.95, a quick ratio of 7.75 and a debt-to-equity ratio of 0.13.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last issued its earnings results on Thursday, April 24th. The company reported ($0.45) EPS for the quarter, beating analysts' consensus estimates of ($0.49) by $0.04. PROCEPT BioRobotics had a negative return on equity of 28.09% and a negative net margin of 36.20%. The business had revenue of $69.16 million during the quarter, compared to analyst estimates of $65.39 million. During the same period in the previous year, the company posted ($0.51) EPS. The firm's revenue was up 55.5% compared to the same quarter last year. As a group, equities analysts expect that PROCEPT BioRobotics Corporation will post -1.75 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the company. Stephens assumed coverage on PROCEPT BioRobotics in a research note on Wednesday. They issued an "overweight" rating and a $70.00 price objective on the stock. Oppenheimer assumed coverage on PROCEPT BioRobotics in a research note on Monday. They issued a "market perform" rating on the stock. Bank of America dropped their price objective on PROCEPT BioRobotics from $104.00 to $84.00 and set a "buy" rating on the stock in a research note on Friday, April 25th. Truist Financial dropped their price objective on PROCEPT BioRobotics from $90.00 to $70.00 and set a "buy" rating on the stock in a research note on Friday, April 11th. Finally, Wall Street Zen raised PROCEPT BioRobotics from a "sell" rating to a "hold" rating in a research note on Saturday, May 24th. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $87.50.

Insider Buying and Selling

In other PROCEPT BioRobotics news, Director Antal Rohit Desai sold 25,000 shares of the business's stock in a transaction that occurred on Thursday, June 12th. The stock was sold at an average price of $61.49, for a total transaction of $1,537,250.00. Following the completion of the sale, the director directly owned 14,363 shares of the company's stock, valued at approximately $883,180.87. The trade was a 63.51% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Over the last three months, insiders sold 100,000 shares of company stock worth $6,271,250. Insiders own 6.60% of the company's stock.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).